Skip to main content
Erschienen in: Critical Care 4/2011

01.08.2011 | Commentary

In vivo and in vitro evidence for pleiotropic effects of levosimendan in the intensive care setting

verfasst von: Mehmet Birhan Yilmaz, Alexandre Mebazaa

Erschienen in: Critical Care | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Levosimendan, in addition to its inotropic properties, could have anti-inflammatory and anti-oxidative properties, and can potentially decrease the deleterious effects of reactive oxygen species on the tissues. In their study, Hasslacher and colleagues provided not only in vitro but also in vivo evidence that levosimendan could preserve organ function in acute heart failure and septic-shock-induced myocardial depression via cooling down the oxidative burst of circulating cells.
Literatur
1.
Zurück zum Zitat Hasslacher J, Bijuklic K, Bertocchi C, Kountchev J, Bellmann R, Dunzendorfer S, Joannidis M: Levosimendan inhibits release of reactive oxygen species in polymorphonuclear neutrophils in vitro and in patients with acute heart failure and septic shock: a prospective observational study. Crit Care. 2011, 15: R166-10.1186/cc10307.PubMedPubMedCentralCrossRef Hasslacher J, Bijuklic K, Bertocchi C, Kountchev J, Bellmann R, Dunzendorfer S, Joannidis M: Levosimendan inhibits release of reactive oxygen species in polymorphonuclear neutrophils in vitro and in patients with acute heart failure and septic shock: a prospective observational study. Crit Care. 2011, 15: R166-10.1186/cc10307.PubMedPubMedCentralCrossRef
2.
Zurück zum Zitat Parissis JT, Andreadou I, Bistola V, Paraskevaidis I, Filippatos G, Kremastinos DT: Novel biologic mechanisms of levosimendan and its effect on the failing heart. Expert Opin Investig Drugs. 2008, 17: 1143-1150. 10.1517/13543784.17.8.1143.PubMedCrossRef Parissis JT, Andreadou I, Bistola V, Paraskevaidis I, Filippatos G, Kremastinos DT: Novel biologic mechanisms of levosimendan and its effect on the failing heart. Expert Opin Investig Drugs. 2008, 17: 1143-1150. 10.1517/13543784.17.8.1143.PubMedCrossRef
3.
Zurück zum Zitat Zager RA, Johnson AC, Lund S, Hanson SY, Abrass CK: Levosimendan protects against experimental endotoxemic acute renal failure. Am J Physiol Renal Physiol. 2006, 290: F1453-F1462. 10.1152/ajprenal.00485.2005.PubMedCrossRef Zager RA, Johnson AC, Lund S, Hanson SY, Abrass CK: Levosimendan protects against experimental endotoxemic acute renal failure. Am J Physiol Renal Physiol. 2006, 290: F1453-F1462. 10.1152/ajprenal.00485.2005.PubMedCrossRef
4.
Zurück zum Zitat Adamopoulos S, Parissis JT, Iliodromitis EK, Paraskevaidis I, Tsiapras D, Farmakis D, Karatzas D, Gheorghiade M, Filippatos GS, Kremastinos DT: Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol. 2006, 98: 102-106. 10.1016/j.amjcard.2006.01.068.PubMedCrossRef Adamopoulos S, Parissis JT, Iliodromitis EK, Paraskevaidis I, Tsiapras D, Farmakis D, Karatzas D, Gheorghiade M, Filippatos GS, Kremastinos DT: Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol. 2006, 98: 102-106. 10.1016/j.amjcard.2006.01.068.PubMedCrossRef
Metadaten
Titel
In vivo and in vitro evidence for pleiotropic effects of levosimendan in the intensive care setting
verfasst von
Mehmet Birhan Yilmaz
Alexandre Mebazaa
Publikationsdatum
01.08.2011
Verlag
BioMed Central
Erschienen in
Critical Care / Ausgabe 4/2011
Elektronische ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc10308

Weitere Artikel der Ausgabe 4/2011

Critical Care 4/2011 Zur Ausgabe

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.